Christopher R. Loose - Jul 7, 2023 Form 4 Insider Report for Frequency Therapeutics, Inc. (FREQ)

Role
Chief Scientific Officer
Signature
/s/ James P. Abely, Attorney-in-Fact for Christopher R. Loose
Stock symbol
FREQ
Transactions as of
Jul 7, 2023
Transactions value $
-$953
Form type
4
Date filed
7/11/2023, 05:35 PM
Previous filing
Jul 7, 2023
Next filing
Jul 13, 2023
SEC
View on sec.gov
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FREQ Common Stock Sale -$470 -1.31K -2.04% $0.36 62.8K Jul 7, 2023 Direct F1, F2, F3
transaction FREQ Common Stock Options Exercise +4.55K +7.24% 67.3K Jul 7, 2023 Direct F4
transaction FREQ Common Stock Sale -$482 -1.3K -1.94% $0.37 66K Jul 10, 2023 Direct F1, F5
transaction FREQ Common Stock Options Exercise +4.55K +6.89% 70.6K Jul 10, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FREQ Restricted Stock Unit Options Exercise -4.55K -3.23% 136K Jul 7, 2023 Common Stock 4.55K Direct F4, F6
transaction FREQ Restricted Stock Unit Options Exercise -4.55K -3.33% 132K Jul 10, 2023 Common Stock 4.55K Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 Includes 6,329 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
F4 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F5 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.37 to $0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F6 The restricted stock units will fully vest on July 4, 2023.